Translarna®

Active substance

ataluren

Holder

PTC Therapeutics France

Status

Running

Indication

Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, inambulatory patients aged 5 years and older for patients who have been treated with this medicinal product as part of the clinical trials (studies 019 and 020E) that are currently in the close-out process.

Public documents

Approbation

Information for the patient

Informed consent

Dernière mise à jour

15/09/2017

Last updated on 28/09/2022